Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers.

Molecular cancer therapeutics 20121001

Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma.

The Annals of pharmacotherapy 20121001

Romidepsin is effective in subcutaneous panniculitis-like T-cell lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120820

Low-dose electron beam radiation and romidepsin therapy for symptomatic cutaneous T-cell lymphoma lesions.

The British journal of dermatology 20120701

Romidepsin for cutaneous T-cell lymphoma.

Clinical cancer research : an official journal of the American Association for Cancer Research 20120701

Phase 1 results from a study of romidepsin in combination with gemcitabine in patients with advanced solid tumors.

Cancer investigation 20120701

Romidepsin for previously treated patients with peripheral or aggressive T-cell lymphomas.

Clinical advances in hematology & oncology : H&O 20120501

The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients.

American journal of hematology 20120401

Romidepsin: a new drug for the treatment of cutaneous T-cell lymphoma.

Clinical journal of oncology nursing 20120401

Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120220

Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy.

Oncogene 20120202

Romidepsin: a guide to its clinical use in cutaneous T-cell lymphoma.

American journal of clinical dermatology 20120201

Synthesis and biochemical analysis of 2,2,3,3,4,4,5,5,6,6,7,7-dodecafluoro-N-hydroxy-octanediamides as inhibitors of human histone deacetylases.

Bioorganic & medicinal chemistry 20120115

HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications.

Immunology and cell biology 20120101

Histone acetyltransferases and deacetylases: molecular and clinical implications to gastrointestinal carcinogenesis.

Acta biochimica et biophysica Sinica 20120101

A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.

Blood 20111208

From the observation DAC: romidepsin revisited.

Blood 20111208

Romidepsin in the treatment of T-cell lymphoma: profile report.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20111201

Largazole and analogues with modified metal-binding motifs targeting histone deacetylases: synthesis and biological evaluation.

Journal of medicinal chemistry 20111110

Thailandepsins: bacterial products with potent histone deacetylase inhibitory activities and broad-spectrum antiproliferative activities.

Journal of natural products 20111028

Histone deacetylase inhibitors from Burkholderia thailandensis.

Journal of natural products 20111028

Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer.

Cell cycle (Georgetown, Tex.) 20110915

Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma.

The Journal of antibiotics 20110801

Romidepsin: a novel histone deacetylase inhibitor for cancer.

Expert opinion on investigational drugs 20110801

Romidepsin: in the treatment of T-cell lymphoma.

Drugs 20110730

Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.

Journal of medicinal chemistry 20110714

Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.

Journal of medicinal chemistry 20110714

[Epigenetic therapy in myelodysplastic syndromes].

[Rinsho ketsueki] The Japanese journal of clinical hematology 20110701

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.

Blood 20110602

Metabolism as a key to histone deacetylase inhibition.

Critical reviews in biochemistry and molecular biology 20110601

A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03.

Neuro-oncology 20110501

Oxime amides as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity, and computational evaluation.

Journal of medicinal chemistry 20110414

The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.

British journal of pharmacology 20110401

Inhibition of transcription, expression, and secretion of the vascular epithelial growth factor in human epithelial endometriotic cells by romidepsin.

Fertility and sterility 20110401

Upregulation of ABCG2 by romidepsin via the aryl hydrocarbon receptor pathway.

Molecular cancer research : MCR 20110401

Differential induction of reactive oxygen species through Erk1/2 and Nox-1 by FK228 for selective apoptosis of oncogenic H-Ras-expressing human urinary bladder cancer J82 cells.

Journal of cancer research and clinical oncology 20110301

Oncogenic H-Ras, FK228, and exogenous H2O2 cooperatively activated the ERK pathway in selective induction of human urinary bladder cancer J82 cell death.

Molecular carcinogenesis 20110301

Impact of ABCB1 allelic variants on QTc interval prolongation.

Clinical cancer research : an official journal of the American Association for Cancer Research 20110215

Coumarin-suberoylanilide hydroxamic acid as a fluorescent probe for determining binding affinities and off-rates of histone deacetylase inhibitors.

Analytical biochemistry 20110115

Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma.

Cancer 20110115

The HDAC inhibitor FK228 enhances adenoviral transgene expression by a transduction-independent mechanism but does not increase adenovirus replication.

PloS one 20110101

Vesicular stomatitis virus infection promotes immune evasion by preventing NKG2D-ligand surface expression.

PloS one 20110101

Romidepsin reduces histone deacetylase activity, induces acetylation of histones, inhibits proliferation, and activates apoptosis in immortalized epithelial endometriotic cells.

Fertility and sterility 20101201

Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies.

Expert opinion on pharmacotherapy 20101201

Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101010

Romidepsin (FK228), a potent histone deacetylase inhibitor, induces apoptosis through the generation of hydrogen peroxide.

Cancer science 20101001

HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells.

Leukemia 20101001

FK228 and oncogenic H-Ras synergistically induce Mek1/2 and Nox-1 to generate reactive oxygen species for differential cell death.

Anti-cancer drugs 20101001

Histone deacetylase inhibitors valproic acid and depsipeptide sensitize retinoblastoma cells to radiotherapy by increasing H2AX phosphorylation and p53 acetylation-phosphorylation.

International journal of oncology 20101001

FK228 induces mitotic catastrophe in A549 cells by mistargeting chromosomal passenger complex localization through changing centromeric H3K9 hypoacetylation.

Acta biochimica et biophysica Sinica 20101001

Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304).

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20101001

Histone deacetylase inhibition as a mechanism for the therapeutic effect of statins (3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors) in follicular lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100820

Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma.

Blood 20100722

Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.

Expert review of anticancer therapy 20100701

The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21.

Cancer biology & therapy 20100601

Romidepsin (Istodax) for cutaneous T-cell lymphoma.

The Medical letter on drugs and therapeutics 20100531

Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.

Cell cycle (Georgetown, Tex.) 20100501

Novel agents in development for peripheral T-cell lymphoma.

Seminars in hematology 20100401

The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma.

Clinical lymphoma, myeloma & leukemia 20100401

Emerging role of epigenetic therapies in cutaneous T-cell lymphomas.

Expert review of hematology 20100401

Chemical phylogenetics of histone deacetylases.

Nature chemical biology 20100301

StatBite: FDA oncology drug product approvals in 2009.

Journal of the National Cancer Institute 20100224

Deal watch: Celgene acquires Gloucester pharmaceuticals, gaining approved HDAC inhibitor.

Nature reviews. Drug discovery 20100201

Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma.

Clinical cancer research : an official journal of the American Association for Cancer Research 20100115

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).

Annals of oncology : official journal of the European Society for Medical Oncology 20100101

Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma.

British journal of haematology 20100101

New drugs: pitavastatin calcium, vigabatrin, and romidepsin.

Journal of the American Pharmacists Association : JAPhA 20100101

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091110

Role of reactive oxygen species in proapoptotic ability of oncogenic H-Ras to increase human bladder cancer cell susceptibility to histone deacetylase inhibitor for caspase induction.

Journal of cancer research and clinical oncology 20091101

Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report.

Haematologica 20091101

Romidepsin for the treatment of cutaneous T-cell lymphoma.

Drugs of today (Barcelona, Spain : 1998) 20091101

Total synthesis of the bicyclic depsipeptide HDAC inhibitors spiruchostatins A and B, 5''-epi-spiruchostatin B, FK228 (FR901228) and preliminary evaluation of their biological activity.

Chemistry (Weinheim an der Bergstrasse, Germany) 20091026

Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336).

Investigational new drugs 20091001

Halogenated fatty acid amides and cyclic depsipeptides from an eastern Caribbean collection of the cyanobacterium Lyngbya majuscula.

Journal of natural products 20090901

Response of retinoic acid-resistant KG1 cells to combination of retinoic acid with diverse histone deacetylase inhibitors.

Annals of the New York Academy of Sciences 20090801

New treatment strategies for Hodgkin's lymphoma.

Leukemia research 20090701

Depsipeptide induces cell death in Hodgkin lymphoma-derived cell lines.

Leukemia research 20090701

An FAD-dependent pyridine nucleotide-disulfide oxidoreductase is involved in disulfide bond formation in FK228 anticancer depsipeptide.

Chemistry & biology 20090626

Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications.

Clinical cancer research : an official journal of the American Association for Cancer Research 20090615

Clinical studies of histone deacetylase inhibitors.

Clinical cancer research : an official journal of the American Association for Cancer Research 20090615

Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.

Anti-cancer drugs 20090601

T-cell lymphomas.

Clinical advances in hematology & oncology : H&O 20090601

Tissue context-activated telomerase in human epidermis correlates with little age-dependent telomere loss.

Biochimica et biophysica acta 20090401

Synthesis and conformation-activity relationships of the peptide isosteres of FK228 and largazole.

Journal of the American Chemical Society 20090304

Involvement of extracellular signal-regulated kinase activation in human osteosarcoma cell resistance to the histone deacetylase inhibitor FK228 [(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone].

The Journal of pharmacology and experimental therapeutics 20090301

Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma.

Clinical cancer research : an official journal of the American Association for Cancer Research 20090215

Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20090201

[Effect of fluorouracil combined with FK228 on the proliferation, apoptosis and Fas mRNA level in HepG2 hepatoma cell lines].

Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 20090201

Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition.

Human molecular genetics 20090115

Induction of autophagy in malignant rhabdoid tumor cells by the histone deacetylase inhibitor FK228 through AIF translocation.

International journal of cancer 20090101

Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors.

PloS one 20090101

Development of an efficient solid-phase synthetic methodology to construct a combinatorial library of a potent HDAC inhibitor.

Advances in experimental medicine and biology 20090101

Macrolactamization versus macrolactonization: total synthesis of FK228, the depsipeptide histone deacetylase inhibitor.

The Journal of organic chemistry 20081205

Efficient solid-phase synthesis of FK228 analogues as potent antitumoral agents.

Journal of medicinal chemistry 20081113

Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia.

Clinical cancer research : an official journal of the American Association for Cancer Research 20081101

Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review).

International journal of oncology 20081001

[Epigenetics in hematological disorders].

[Rinsho ketsueki] The Japanese journal of clinical hematology 20081001

Aurora A, Aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer.

Cancer biology & therapy 20080901

[How and why was a histone deacetylase inhibitor created?].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20080901

Total synthesis and biological mode of action of largazole: a potent class I histone deacetylase inhibitor.

Journal of the American Chemical Society 20080820

Proteomic analysis identifies protein targets responsible for depsipeptide sensitivity in tumor cells.

Journal of proteome research 20080701

[FK228 promotes the IL-3 mediated proliferation and differentiation of human erythroid progenitor cells].

Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology 20080701

Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma.

The Journal of investigative dermatology 20080601

Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma.

Cancer research 20080601

Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models.

Molecular cancer therapeutics 20080601

Inhibition of histone deacetylase1 induces autophagy.

Biochemical and biophysical research communications 20080516

Instability of retroviral DNA methylation in embryonic stem cells.

Stem cells (Dayton, Ohio) 20080501

Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin.

Molecular cancer therapeutics 20080501

Determination of the cyclic depsipeptide FK228 in human and mouse plasma by liquid chromatography with mass-spectrometric detection.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080401

Histone deacetylase inhibitor FK228 enhances adenovirus-mediated p53 family gene therapy in cancer models.

Molecular cancer therapeutics 20080401

The depsipeptide technique applied to peptide segment condensation: scope and limitations.

Journal of peptide science : an official publication of the European Peptide Society 20080301

Histone deacetylase inhibitors in lymphoma and solid malignancies.

Expert review of anticancer therapy 20080301

Improved total synthesis of the potent HDAC inhibitor FK228 (FR-901228).

Organic letters 20080221

Effect of trans-2,3-dimethoxycinnamoyl azide on enhancing antitumor activity of romidepsin on human bladder cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research 20080215

Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20080201

Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes.

Clinical cancer research : an official journal of the American Association for Cancer Research 20080201

Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.

Clinical cancer research : an official journal of the American Association for Cancer Research 20080115

Clinical and molecular responses in lung cancer patients receiving Romidepsin.

Clinical cancer research : an official journal of the American Association for Cancer Research 20080101

Inhibition of histone deacetylase down-regulates the expression of hypoxia-induced vascular endothelial growth factor by rheumatoid synovial fibroblasts.

Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20080101

Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells.

Molecular cancer research : MCR 20080101

Depsipeptide (FK228) inhibits growth of human prostate cancer cells.

Urologic oncology 20080101

Histone deacetylase inhibitors from microorganisms: the Astellas experience.

Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques 20080101

Role of histone deacetylase inhibitor in adenovirus-mediated p53 gene therapy in esophageal cancer.

Anticancer research 20080101

Molecular regulation of MHC class I chain-related protein A expression after HDAC-inhibitor treatment of Jurkat T cells.

Journal of immunology (Baltimore, Md. : 1950) 20071215

Tissue-targeted in vivo gene transfer coupled with histone deacetylase inhibitor depsipeptide (FK228) enhances adenoviral infection in rat renal cancer allograft model systems.

Urology 20071201

The first biologically active synthetic analogues of FK228, the depsipeptide histone deacetylase inhibitor.

Journal of medicinal chemistry 20071115

Pro-apoptotic activity of oncogenic H-Ras for histone deacetylase inhibitor to induce apoptosis of human cancer HT29 cells.

Journal of cancer research and clinical oncology 20071001

Depsipeptide (FK228) as a novel histone deacetylase inhibitor: mechanism of action and anticancer activity.

Mini reviews in medicinal chemistry 20071001

Gene expression profiling induced by histone deacetylase inhibitor, FK228, in human esophageal squamous cancer cells.

Oncology reports 20070901

Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1.

Cell death and differentiation 20070801

Enhanced therapeutic effect on androgen-independent prostate cancer by depsipeptide (FK228), a histone deacetylase inhibitor, in combination with docetaxel.

Urology 20070801

[EPO mediated proliferation and differentiation of human erythroid progenitor inhibited by FK228].

Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology 20070601

Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.

Stem cells and development 20070601

FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70.

Biochemical and biophysical research communications 20070518

Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy.

Cancer biology & therapy 20070501

The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy.

International journal of cancer 20070415

Low concentrations of the histone deacetylase inhibitor, depsipeptide, enhance the effects of gemcitabine and docetaxel in hormone refractory prostate cancer cells.

Oncology reports 20070401

The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells.

Cancer gene therapy 20070301

A histone deacetylase inhibitor enhances adenoviral infection of renal cancer cells.

The Journal of urology 20070301

Proapoptotic ability of oncogenic H-Ras to facilitate apoptosis induced by histone deacetylase inhibitors in human cancer cells.

Molecular cancer therapeutics 20070301

[Fermentation research on natural products derived from micro-organisms for the discovery of new drugs].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20070301

Depsipeptide a histone deacetlyase inhibitor down regulates levels of matrix metalloproteinases 2 and 9 mRNA and protein expressions in lung cancer cells (A549).

Chemico-biological interactions 20070220

Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.

Investigational new drugs 20070201

HDAC inhibitors and cardiac safety.

Clinical cancer research : an official journal of the American Association for Cancer Research 20070201

The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systems.

Molecular cancer therapeutics 20070201

[The inhibitory effects of FK228 on retinal neovascularization].

[Zhonghua yan ke za zhi] Chinese journal of ophthalmology 20070201

Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors).

Cancer letters 20070108

The histone deacetylase inhibitor FK228 may have therapeutic usefulness to prevent suicidal behaviour via upregulation of the guanosine triphosphatase Rap-1.

Medical hypotheses 20070101

Utilization of chromatin remodeling agents for lung cancer therapy.

Cancer journal (Sudbury, Mass.) 20070101

Histone deacetylase inhibitors in combinations: will the preclinical promises be kept?

Cancer journal (Sudbury, Mass.) 20070101

Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells.

Cancer journal (Sudbury, Mass.) 20070101

Systemic co-administration of depsipeptide selectively targets transfection enhancement to specific tissues and cell types.

Gene therapy 20061201

Histone deacetylase inhibitor FK228 is a potent inducer of human fetal hemoglobin.

American journal of hematology 20061201

The histone deacetylase inhibitor FK228 distinctly sensitizes the human leukemia cells to retinoic acid-induced differentiation.

Annals of the New York Academy of Sciences 20061201

FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities.

Cancer chemotherapy and pharmacology 20061101

Targeting the epigenome for the treatment of thoracic malignancies.

Thoracic surgery clinics 20061101

Targeting of interstitial cells using a simple gene-transfer strategy.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20061001

Pleiotropic role of histone deacetylases in the regulation of human adult erythropoiesis.

British journal of haematology 20061001

Bmf contributes to histone deacetylase inhibitor-mediated enhancing effects on apoptosis after ionizing radiation.

Apoptosis : an international journal on programmed cell death 20060801

Histone deacetylase inhibitors enhance phosphorylation of histone H2AX after ionizing radiation.

International journal of radiation oncology, biology, physics 20060701

Cardiac safety, risk management, and oncology drug development.

Clinical cancer research : an official journal of the American Association for Cancer Research 20060615

Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma.

Clinical cancer research : an official journal of the American Association for Cancer Research 20060615

Depsipeptide-resistant KU812 cells show reversible P-glycoprotein expression, hyper-acetylated histones, and modulated gene expression profile.

Leukemia research 20060601

Defining the role of gene regulation in resistance to HDAC inhibitors--mechanisms beyond P-glycoprotein.

Leukemia research 20060601

Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates.

Cancer research 20060601

Histone post-translational modification: from discovery to the clinic.

IDrugs : the investigational drugs journal 20060601

A phase II study of depsipeptide in refractory metastatic renal cell cancer.

Clinical genitourinary cancer 20060601

A histone deacetylase inhibitor enhances recombinant adeno-associated virus-mediated gene expression in tumor cells.

Molecular therapy : the journal of the American Society of Gene Therapy 20060401

Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176).

Clinical cancer research : an official journal of the American Association for Cancer Research 20060301

Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells.

Blood 20060215

Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.

Experimental cell research 20060201

Histone deacetylase inhibitor FK228 suppresses the Ras-MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma.

Oncogene 20060126

Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis.

Cell death and differentiation 20060101

Involvement of P-glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells.

International journal of cancer 20060101

Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.

Acta haematologica 20060101

Histone deacetylase inhibitors in cancer therapy.

Cancer investigation 20060101

Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B.

Cancer research 20051201

Effect of the histone deacetylase inhibitor depsipeptide on B-cell differentiation in both TEL-AML1-positive and negative childhood acute lymphoblastic leukemia.

Haematologica 20051201

Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-beta production.

Journal of immunology (Baltimore, Md. : 1950) 20051101

Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells.

Clinical cancer research : an official journal of the American Association for Cancer Research 20051101

Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors.

International journal of cancer 20050920

A putative role for histone deacetylase in the differentiation of human erythroid cells.

International journal of oncology 20050901

Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance.

Cancer biology & therapy 20050901

Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors.

Cancer research 20050815

Enhanced transgene expression in urothelial cancer gene therapy with histone deacetylase inhibitor.

The Journal of urology 20050801

Synergistic induction of DOC-2/DAB2 gene expression in transitional cell carcinoma in the presence of GATA6 and histone deacetylase inhibitor.

Cancer research 20050715

Accumulation of hypoxia-inducible factor-1alpha is limited by transcription-dependent depletion.

Oncogene 20050714

Effects of histone deacetylase inhibitor FR901228 on the expression level of telomerase reverse transcriptase in oral cancer.

Cancer chemotherapy and pharmacology 20050701

Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines.

The Journal of pharmacology and experimental therapeutics 20050701

Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo.

Cancer letters 20050628

Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228).

Journal of cellular physiology 20050501

Interference of CREB-dependent transcriptional activation by expanded polyglutamine stretches--augmentation of transcriptional activation as a potential therapeutic strategy for polyglutamine diseases.

Journal of neurochemistry 20050501

Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin.

Cell cycle (Georgetown, Tex.) 20050501

Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1.

The Journal of pharmacology and experimental therapeutics 20050401

Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts.

Molecular therapy : the journal of the American Society of Gene Therapy 20050401

Signal therapy of NF1-deficient tumor xenograft in mice by the anti-PAK1 drug FK228.

Cancer biology & therapy 20050401

Sequential 5-Aza 2'-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells.

Oncogene 20050331

[Histone deacetylase inhibitors as a new generation of anti-cancer agents].

Postepy higieny i medycyny doswiadczalnej (Online) 20050311

Suppression of phosphatidylinositol 3-kinase/Akt signaling pathway is a determinant of the sensitivity to a novel histone deacetylase inhibitor, FK228, in lung adenocarcinoma cells.

Oncology reports 20050301

Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor.

Biochemical pharmacology 20050215

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.

Blood 20050201

Distinct roles of the ERK pathway in modulating apoptosis of Ras-transformed and non-transformed cells induced by anticancer agent FR901228.

FEBS letters 20050103

Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP.

Cell death and differentiation 20050101

Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes.

Biological & pharmaceutical bulletin 20050101

The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells.

Molecular cancer therapeutics 20041101

[A histone deacetylase inhibitor and tumor suppressing gene p53 induction synergistically induce apoptosis of cancer cells].

[Hokkaido igaku zasshi] The Hokkaido journal of medical science 20041101

Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.

Journal of the National Cancer Institute 20041006

Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression.

Arthritis and rheumatism 20041001

Determination of the cyclic depsipeptide FK228, a histone deacetylase inhibitor, by liquid chromatography-mass spectrometry.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040925

Potentiation of androgen receptor transcriptional activity by inhibition of histone deacetylation--rescue of transcriptionally compromised mutants.

The Journal of endocrinology 20040901

[Violacein: a molecule of biological interest originating from the soil-borne bacterium Chromobacterium violaceum].

La Revue de medecine interne 20040901

Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates.

Cancer chemotherapy and pharmacology 20040701

Effects of demethylating agent 5-aza-2(')-deoxycytidine and histone deacetylase inhibitor FR901228 on maspin gene expression in oral cancer cell lines.

Oral oncology 20040701

Histone deacetylase inhibitors FK228, N-(2-aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)amino- methyl]benzamide and m-carboxycinnamic acid bis-hydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells.

International journal of cancer 20040610

Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin.

Endocrinology 20040601

Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo.

Acta neuropathologica 20040601

Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors.

Radiation research 20040601

Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells.

Clinical cancer research : an official journal of the American Association for Cancer Research 20040601

Impact of novel histone deacetylase inhibitors, CHAP31 and FR901228 (FK228), on adenovirus-mediated transgene expression.

The journal of gene medicine 20040501

Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma.

British journal of haematology 20040401

FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells.

International journal of oncology 20040301

Genomic surgery for lung cancer.

The Journal of surgical research 20040301

Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells.

Clinical cancer research : an official journal of the American Association for Cancer Research 20040301

Lack of preventive efficacy of FK228, a histone deacetylase inhibitor, against N-butyl-N-(4-hydroxybutyl) nitrosamine-induced urinary bladder carcinogenesis in p53+/- and p53+/+ mice.

Anticancer research 20040101

A review of depsipeptide and other histone deacetylase inhibitors in clinical trials.

Current pharmaceutical design 20040101

Depsipeptide enhances imatinib mesylate-induced apoptosis of Bcr-Abl-positive cells and ectopic expression of cyclin D1, c-Myc or active MEK abrogates this effect.

Anticancer research 20040101

FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells.

Oncogene 20031218

The histone deacetylase inhibitor FK228 preferentially enhances adenovirus transgene expression in malignant cells.

Clinical cancer research : an official journal of the American Association for Cancer Research 20031101

Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors.

Biochemical pharmacology 20030915

Novel mechanisms of apoptosis induced by histone deacetylase inhibitors.

Cancer research 20030801

Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein.

Blood 20030715

Effects of FK228, a novel histone deacetylase inhibitor, on tumor growth and expression of p21 and c-myc genes in vivo.

Cancer letters 20030610

Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines.

Investigative ophthalmology & visual science 20030601

Histone deacetylase inhibitors activate p21(WAF1) expression via ATM.

Cancer research 20030601

Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2'-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells.

Leukemia research 20030501

Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway.

The Journal of thoracic and cardiovascular surgery 20030501

Antiproliferative effects of the histone deacetylase inhibitor FR901228 on small-cell lung cancer lines and drug-resistant sublines.

International journal of cancer 20030320

Interaction of 5-aza-2'-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells.

Anti-cancer drugs 20030301

A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma.

Cancer gene therapy 20030301

Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells.

Leukemia 20030201

Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity.

Biochemical and biophysical research communications 20030103

Identification of thiols and glutathione conjugates of depsipeptide FK228 (FR901228), a novel histone protein deacetylase inhibitor, in the blood.

Rapid communications in mass spectrometry : RCM 20030101

Profiling of cyclic hexadepsipeptides roseotoxins synthesized in vitro and in vivo: a combined tandem mass spectrometry and quantum chemical study.

European journal of mass spectrometry (Chichester, England) 20030101

Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo.

Biochemical pharmacology 20021001

A histone deacetylase inhibitor enhances killing of undifferentiated thyroid carcinoma cells by p53 gene therapy.

The Journal of clinical endocrinology and metabolism 20021001

FR901228, an inhibitor of histone deacetylases, increases the cellular responsiveness to IL-6 type cytokines by enhancing the expression of receptor proteins.

Oncogene 20020912

FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases.

Cancer research 20020901

Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity.

Molecular cancer therapeutics 20020901

FR-901228 Fujisawa/National Cancer Institute.

Current opinion in investigational drugs (London, England : 2000) 20020901

38th annual meeting of the American Society of Clinical Oncology.

Clinical lymphoma 20020601

Regulation of activation-induced receptor activator of NF-kappaB ligand (RANKL) expression in T cells.

European journal of immunology 20020401

Histone deacetylase inhibitor FR901228 enhances adenovirus infection of hematopoietic cells.

Blood 20020315

Differential modulation of signaling pathways and apoptosis of ras-transformed 10T1/2 cells by the depsipeptide FR901228.

The Journal of pharmacology and experimental therapeutics 20020301

Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment.

Clinical cancer research : an official journal of the American Association for Cancer Research 20020301

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.

Clinical cancer research : an official journal of the American Association for Cancer Research 20020301

Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis.

International journal of cancer 20020120

A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.

Journal of experimental therapeutics & oncology 20020101

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report.

Blood 20011101

Inhibitors of histone deacetylase as new anticancer agents.

Current medicinal chemistry 20011001

Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228.

Cancer research 20010901

Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells.

The Journal of clinical endocrinology and metabolism 20010701

In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD / Shi-scid/scid mice.

Japanese journal of cancer research : Gann 20010501

Construction of gene therapy vectors targeting thyroid cells: enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the cyclic adenosine 3',5'-monophosphate pathway and demonstration of activity in follicular and anaplastic thyroid carcinoma cells.

The Journal of clinical endocrinology and metabolism 20010201

Induction of MAGE-3 expression in lung and esophageal cancer cells.

The Annals of thoracic surgery 20010101

Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1.

Journal of immunotherapy (Hagerstown, Md. : 1997) 20010101